BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25294846)

  • 1. VEGFR2-Targeted Ultrasound Imaging Agent Enhances the Detection of Ovarian Tumors at Early Stage in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer.
    Barua A; Yellapa A; Bahr JM; Machado SA; Bitterman P; Basu S; Sharma S; Abramowicz JS
    Ultrason Imaging; 2015 Jul; 37(3):224-37. PubMed ID: 25294846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of ovarian tumor detection with αvβ3 integrin-targeted ultrasound molecular imaging agent in laying hens: a preclinical model of spontaneous ovarian cancer.
    Barua A; Yellapa A; Bahr JM; Machado SA; Bitterman P; Basu S; Sharma S; Abramowicz JS
    Int J Gynecol Cancer; 2014 Jan; 24(1):19-28. PubMed ID: 24304684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 16- (IL-16-) Targeted Ultrasound Imaging Agent Improves Detection of Ovarian Tumors in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer.
    Barua A; Yellapa A; Bahr JM; Adur MK; Utterback CW; Bitterman P; Basu S; Sharma S; Abramowicz JS
    Biomed Res Int; 2015; 2015():567459. PubMed ID: 26161406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of Ovarian Tumor Detection by DR6-Targeted Ultrasound Imaging Agents in Laying Hen Model of Spontaneous Ovarian Cancer.
    Barua A; Edassery SL; McNeal S; Bahr JM; Bitterman P; Basu S; Sharma S; Abramowicz JS
    Int J Gynecol Cancer; 2016 Oct; 26(8):1375-85. PubMed ID: 27465898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of tumor-associated neoangiogenesis by Doppler ultrasonography during early-stage ovarian cancer in laying hens: a preclinical model of human spontaneous ovarian cancer.
    Barua A; Bitterman P; Bahr JM; Bradaric MJ; Hales DB; Luborsky JL; Abramowicz JS
    J Ultrasound Med; 2010 Feb; 29(2):173-82. PubMed ID: 20103787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer.
    Yellapa A; Bahr JM; Bitterman P; Abramowicz JS; Edassery SL; Penumatsa K; Basu S; Rotmensch J; Barua A
    Int J Gynecol Cancer; 2012 Feb; 22(2):199-207. PubMed ID: 22274315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced sonography depicts spontaneous ovarian cancer at early stages in a preclinical animal model.
    Barua A; Bitterman P; Bahr JM; Basu S; Sheiner E; Bradaric MJ; Hales DB; Luborsky JL; Abramowicz JS
    J Ultrasound Med; 2011 Mar; 30(3):333-45. PubMed ID: 21357555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic Ovarian Condition May Be a Risk Factor for Ovarian Tumor Development in the Laying Hen Model of Spontaneous Ovarian Cancer.
    Lee HJ; Bahr JM; Bitterman P; Basu S; Sharma S; Abramowicz JS; Barua A
    J Immunol Res; 2018; 2018():2590910. PubMed ID: 30596106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
    Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
    Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 16 expression changes in association with ovarian malignant transformation.
    Yellapa A; Bitterman P; Sharma S; Guirguis AS; Bahr JM; Basu S; Abramowicz JS; Barua A
    Am J Obstet Gynecol; 2014 Mar; 210(3):272.e1-10. PubMed ID: 24380743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.
    Barua A; Yellapa A; Bahr JM; Abramowicz JS; Edassery SL; Basu S; Rotmensch J; Bitterman P
    Transl Oncol; 2012 Aug; 5(4):260-8. PubMed ID: 22937178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer.
    Paris EA; Bahr JM; Bitterman P; Basu S; Abramowicz JS; Barua A
    PLoS One; 2021; 16(7):e0255007. PubMed ID: 34314463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian Cancer: Applications of Chickens to Humans.
    Barua A; Bahr JM
    Annu Rev Anim Biosci; 2022 Feb; 10():241-257. PubMed ID: 35167319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    Willmann JK; Lutz AM; Paulmurugan R; Patel MR; Chu P; Rosenberg J; Gambhir SS
    Radiology; 2008 Sep; 248(3):936-44. PubMed ID: 18710985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer.
    Barua A; Bitterman P; Abramowicz JS; Dirks AL; Bahr JM; Hales DB; Bradaric MJ; Edassery SL; Rotmensch J; Luborsky JL
    Int J Gynecol Cancer; 2009 May; 19(4):531-9. PubMed ID: 19509547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-Regulated Protein 78 Is a Potential Serum and Imaging Marker for Early Detection of Ovarian Cancer.
    Paris EA; Bahr JM; Abramowicz JS; Basu S; Barua A
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
    Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.
    Khan MF; Bahr JM; Yellapa A; Bitterman P; Abramowicz JS; Edassery SL; Basu S; Rotmensch J; Barua A
    Transl Oncol; 2012 Apr; 5(2):85-91. PubMed ID: 22496924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary supplementation of Ashwagandha (Withania somnifera, Dunal) enhances NK cell function in ovarian tumors in the laying hen model of spontaneous ovarian cancer.
    Barua A; Bradaric MJ; Bitterman P; Abramowicz JS; Sharma S; Basu S; Lopez H; Bahr JM
    Am J Reprod Immunol; 2013 Dec; 70(6):538-50. PubMed ID: 24188693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.